ANTX sentiment intelligence

Price to book forward of AN2 Therapeutics, Inc. – NASDAQ:ANTX

This article provides access to the "Price to book forward" financial metric for AN2 Therapeutics, Inc. (NASDAQ: ANTX) on the TradingView platform. It highlights that the market is closed and no trades have occurred for this specific metric, with data provided by ICE Data Service

Tone

Neutral 50/100

Event

Market update

Published

14 Jul 2026 14:40

Source

TradingView

Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks

Tone

Neutral 50/100

Event

Earnings

Published

13 Jul 2026 12:30

Source

Market source

Form 4 AN2 Therapeutics Inc For: 10 July By Investing.com

This article provides details about a Form 4 filing for AN2 Therapeutics Inc. on July 10, 2026. It mentions the company's stock symbol ANTX and includes a Reuters image. The filing date is explicitly stated as July 10, 2026.

Tone

Neutral 50/100

Event

Market update

Published

11 Jul 2026 12:39

Source

Investing.com Nigeria

AN2 Therapeutics (ANTX) officer sale covers RSU tax withholding, retains 206,554 shares

AN2 Therapeutics officer Joshua M. Eizen sold 5,945 shares of common stock at $4.172 per share on July 8, 2026. This sale was explicitly for tax withholding obligations from Restricted Stock Unit vesting and not a discretionary transaction. After this sale, Eizen still holds 206,

Tone

Neutral 50/100

Event

Market update

Published

11 Jul 2026 12:10

Source

Stock Titan

AN2 Therapeutics (ANTX) director granted 766 shares in lieu of cash fees

AN2 Therapeutics (ANTX) director Patricia A. Martin received a grant of 766 shares of common stock on July 10, 2026. These shares were awarded in lieu of cash fees as per the company's non-employee director compensation policy and vested immediately. This transaction increases he

Tone

Neutral 50/100

Event

Balance sheet

Published

11 Jul 2026 00:09

Source

Stock Titan

AN2 Therapeutics (ANTX) director receives 2,789-share stock grant in lieu of cash

AN2 Therapeutics director Gilbert Lynn Marks received a grant of 2,789 shares of common stock on July 10, 2026, as compensation instead of cash, with the shares vesting immediately. This transaction, made under the company's non-employee director compensation policy, increases Ma

Tone

Neutral 50/100

Event

Balance sheet

Published

11 Jul 2026 00:09

Source

Stock Titan

AN2 Therapeutics (ANTX) director Aziz Kabeer granted 2,852 shares as fees

Aziz Kabeer, a director at AN2 Therapeutics (ANTX), received a grant of 2,852 shares of common stock on July 10, 2026, as compensation for his non-employee director services, issued in lieu of cash. These shares vested immediately, and following this transaction, Kabeer directly

Tone

Neutral 50/100

Event

Balance sheet

Published

11 Jul 2026 00:09

Source

Stock Titan

An2 therapeutics COO Joshua Eizen sells $24,802 in stock

Joshua M. Eizen, COO and Chief Legal Officer at AN2 Therapeutics, Inc. (NASDAQ:ANTX), sold 5,945 shares of company stock for $24,802 to cover tax withholding obligations from vested RSUs. Following the sale, Eizen still holds 206,554 shares, including various tranches of RSUs and

Tone

Neutral 50/100

Event

Market update

Published

10 Jul 2026 23:09

Source

Investing.com

An2 therapeutics COO Joshua Eizen sells $24,802 in stock By Investing.com

Joshua M. Eizen, COO and Chief Legal Officer at AN2 Therapeutics (NASDAQ:ANTX), sold 5,945 shares of company stock worth $24,802 to cover tax obligations from RSU vesting. Following the sale, Eizen still holds 206,554 shares. AN2 Therapeutics, while not yet profitable, has a stro

Tone

Neutral 50/100

Event

Market update

Published

10 Jul 2026 22:10

Source

Investing.com Canada

AN2 Therapeutics Slides 5.96% as Biotech Headwinds Pressure ANTX Shares - Naked POC

Tone

Neutral 50/100

Event

Market update

Published

03 Jul 2026 17:41

Source

dars.gov.et

AN2 Therapeutics, Inc.(NasdaqGS: ANTX) added to Russell 3000E Value Benchmark

Tone

Neutral 50/100

Event

Market update

Published

28 Jun 2026 07:00

Source

marketscreener.com

AN2 Therapeutics, Inc. Actuals & Estimates (NASDAQ:ANTX)

AN2 Therapeutics, Inc. (NASDAQ: ANTX) stock has seen significant growth, with a 377.06% increase over the last year. Analysts have a consistent price target of $9.00 USD. The company's market capitalization stands at $185.12 million, and its next earnings report is expected on Au

Tone

Neutral 50/100

Event

Earnings

Published

26 Jun 2026 08:39

Source

TradingView

Price to earnings forward of AN2 Therapeutics, Inc. – NASDAQ:ANTX

This article provides the "Price to earnings forward" value for AN2 Therapeutics, Inc. (NASDAQ: ANTX) within the context of TradingView's financial data. It indicates the stock's market status and references the data sources used. The specific financial value is not detailed, but

Tone

Neutral 50/100

Event

Earnings

Published

26 Jun 2026 05:11

Source

TradingView

AN2 Therapeutics Inc (ANTX) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for AN2 Therapeutics Inc (ANTX), highlighting an analyst rating of "Strong Buy" based on one analyst's assessment. It includes the current stock price, market cap, and projected target price, along with recent and expected EPS figures. T

Tone

Neutral 50/100

Event

Earnings

Published

17 Jun 2026 21:09

Source

TradingKey

AN2 Therapeutics Inc (ANTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey attempts to provide a revenue breakdown for AN2 Therapeutics Inc (ANTX) but states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. It provides current stock informat

Tone

Neutral 50/100

Event

Earnings

Published

17 Jun 2026 05:39

Source

TradingKey

Number of shareholders of AN2 Therapeutics, Inc. – NASDAQ:ANTX

This article provides details on the number of shareholders for AN2 Therapeutics, Inc. (NASDAQ: ANTX). It presents a table with "Period," "Value," and "Change %" columns, though the data itself is not displayed in the provided content. The information is sourced from ICE Data Ser

Tone

Neutral 50/100

Event

Market update

Published

13 Jun 2026 17:09

Source

TradingView

AN2 Therapeutics Holds 2026 Annual Stockholder Meeting

AN2 Therapeutics, Inc. held its 2026 annual meeting on June 3, 2026, where stockholders elected three Class I directors and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm. Despite concerns about weak financial performance, the company's s

Tone

Neutral 50/100

Event

Market update

Published

10 Jun 2026 14:10

Source

The Globe and Mail

Shareholders back AN2 Therapeutics (NASDAQ: ANTX) directors and auditor

AN2 Therapeutics, Inc. reported the results of its 2026 annual meeting of stockholders, where a quorum of 63.18% of outstanding shares was present. Shareholders elected Kabeer Aziz, Gilbert Lynn Marks, M.D., and Rob Readnour, Ph.D., as Class I directors until the 2029 annual meet

Tone

Neutral 50/100

Event

Earnings

Published

09 Jun 2026 22:10

Source

Stock Titan

AN2 Therapeutics (ANTX) officer sells 265 shares to cover RSU taxes

AN2 Therapeutics Principal Accounting Officer Sarah Joanne Williams sold 265 shares of common stock at $4.43 per share. This transaction was not a discretionary sale but rather a routine tax-related event to satisfy withholding obligations from vested Restricted Stock Units (RSUs

Tone

Neutral 50/100

Event

Market update

Published

02 Jun 2026 20:19

Source

Stock Titan

AN2 Therapeutics (ANTX) Slides 2.9% as Shares Test Key Support Near $4.11 - Regression Channel

Tone

Neutral 50/100

Event

Market update

Published

29 May 2026 07:00

Source

DonanımHaber

AN2 Therapeutics (ANTX) Slides 2.7% as Shares Test Support Near $4.27 - Wyckoff Distribution

Tone

Neutral 50/100

Event

Market update

Published

28 May 2026 07:00

Source

dars.gov.et